VenusX Medical Linear Accelerator Obtains US FDA Clearance


Suzhou LinaTech Medical Technology Co., Ltd.’s self-developed and manufactured VenusX medical linear accelerator obtained clearance from the U.S. Food and Drug Administration (FDA) on April 13, 2024 (K232489). This milestone marks another major breakthrough in LinaTech’s internationalization and global development, further proving that LinaTech holds independent intellectual property rights and fully controllable core technologies. This approval will facilitate global sales of the company’s products and bring new opportunities for business growth and development.

At the end of 2023, the national key R&D program under the 14th Five-Year Plan — the intelligent robot key special project “Real-time Precision Regulation Tumor Radiotherapy System for Moving Target Pose (2023YFB706200)” led by LinaTech was officially approved. In April this year, VenusX obtained US FDA clearance, bringing double celebrations to the company. All employees of LinaTech are overjoyed and fully prepared.

 

图片35.png

 

We believe guided by national policies, LinaTech will cooperate with research institutes and hospitals to further increase R&D investment in “robotic accelerators” and accelerate VenusX exports. Moving forward, based on scientific and technological innovation and high-standard product development, LinaTech will provide radiotherapy equipment support for China’s Belt and Road medical cooperation, deliver high-end Chinese intelligent manufacturing medical equipment to the world, benefit a large number of cancer patients and demonstrate China’s scientific and technological strength.

 

Recommended Reading

Hotline:+86 10 67888916

Time:8:00 - 18:00